Despite significant advances in the development of new antiretroviral drugs for the treatment of HIV-1 infection, elimination of HIV-1 latent sanctuaries and the ability to discontinue HAART are not practically feasible since the viral loads rebound upon cessation of treatment. The reservoir of latently-infected, resting CD4+ T cells is extremely long-lived and can persist for decades in patients receiving antiretroviral therapy. The complete elimination of HIV-1 within a patient will therefore likely require novel clinical approaches to purge the reservoir of latently infected cells. We have shown that combinations of pharmacologic agents act synergistically to activate transcription of a broad spectrum of clinically relevant HIV strains. We propose to extend these studies by testing the latency activation potential of small activating RNAs (saRNAs), which are targeted to promoter regions and activate transcription by guiding epigenetic changes in promoter regions. These saRNAs will be tested both as a stand-alone mechanism for latency activation as well as in combination with select pharmacologic agents known to activate latent viral reservoirs. Once viral transcription is activated viral proteins are made, providing selective therapeutic targets fr targeted therapies. We propose to exploit the expression of the HIV-1 envelope protein (gp120) on the surface of infected cells as a target for aptamer mediated delivery of cytotoxic small interfering RNAs (siRNAs) which will selectively eradicate cells harboring actively replicating HIV-1. The proposed approaches are designed to optimize latency activation and subsequently purge patients of their HIV infected reservoirs. We propose to test these novel strategies in cell culture and in a humanized mouse model that supports active and latent HIV-1 infection. If successful, the proposed approaches will create a new paradigm for the eradication of HIV- 1 infection.
Latent reservoirs of infected cells pose the greatest obstacle to curing patients of HIV-1. The proposed studies will test new approaches for activation of latent virus replication in vitro and in vivo. The long term goal of these studies is the establishment of a method for activation of latent virus followed by selective purging of these cells from infected individuals, ultimately leading to a cure from HIV-1 infection.
|Zhou, Jiehua; Rossi, John (2014) Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy. J Investig Med 62:914-9|
|Song, Min-Sun; Rossi, John J (2014) The anti-miR21 antagomir, a therapeutic tool for colorectal cancer, has a potential synergistic effect by perturbing an angiogenesis-associated miR30. Front Genet 4:301|
|Snead, Nicholas M; Wu, Xiwei; Li, Arthur et al. (2013) Molecular basis for improved gene silencing by Dicer substrate interfering RNA compared with other siRNA variants. Nucleic Acids Res 41:6209-21|
|Zhou, Jiehua; Neff, C Preston; Swiderski, Piotr et al. (2013) Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther 21:192-200|
|Akkina, Ramesh (2013) New generation humanized mice for virus research: comparative aspects and future prospects. Virology 435:14-28|
|Zhou, Jiehua; Shum, Ka-To; Burnett, John C et al. (2013) Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) 6:85-107|
|Neff, Charles Preston; Zhou, Jiehua; Remling, Leila et al. (2011) An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med 3:66ra6|
|Sun, Guihua; Rossi, John J (2011) MicroRNAs and their potential involvement in HIV infection. Trends Pharmacol Sci 32:675-81|
|Zhou, Jiehua; Neff, C Preston; Liu, Xiaoxuan et al. (2011) Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther 19:2228-38|
|Sakurai, Kumi; Amarzguioui, Mohammed; Kim, Dong-Ho et al. (2011) A role for human Dicer in pre-RISC loading of siRNAs. Nucleic Acids Res 39:1510-25|
Showing the most recent 10 out of 39 publications